Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
stocks
4 ASX shares that could be vulnerable to an August surprise
stocks
Another incredible quarter from Microsoft
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,917.10 | 81.90 | -0.91% |
CAC 40 | 7,546.16 | 225.81 | -2.91% |
DAX 40 | 23,425.97 | 639.50 | -2.66% |
Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
FTSE 100 | 9,068.58 | 64.23 | -0.70% |
HKSE | 24,507.81 | 265.52 | -1.07% |
NASDAQ | 20,650.13 | 472.31 | -2.24% |
Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
S&P 500 | 6,238.01 | 101.38 | -1.60% |
S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
SSE Composite Index | 3,559.95 | 13.26 | -0.37% |